Global Dementia and Movement Disorder Treatment Market 2024-2028

The dementia and movement disorder treatment market is forecasted to grow by USD 8.55 bn during 2023-2028, accelerating at a CAGR of 7.28% during the forecast period. The report on the dementia and movement disorder treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing geriatric population, rising prevalence of target diseases, and emergence of strategies to increase public awareness.

Market Scope
Base Year	2024
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	6.63%
CAGR	7.28%
Incremental Value	$8.55bn

Technavio's dementia and movement disorder treatment market is segmented as below:

By Application

Movement disorders
Progressive dementia
Progressive dementia with neurological abnormality (PDNA)

By Drug Class

MAO inhibitors
Acetylcholinesterase inhibitors
Glutamate inhibitors
Others

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the emergence of biomarkers as one of the prime reasons driving the dementia and movement disorder treatment market growth during the next few years. Also, growth of gene therapy to reverse cognitive decline associated with Alzheimer's disease and advances in biomedical science will lead to sizable demand in the market.

The report on the dementia and movement disorder treatment market covers the following areas:

Dementia and movement disorder treatment market sizing
Dementia and movement disorder treatment market forecast
Dementia and movement disorder treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading dementia and movement disorder treatment market vendors that include AbbVie Inc., Acorda Therapeutics Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Biogen Inc., Eisai Co. Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson, Kirin Holdings Co. Ltd., Lannett Co. Inc., Merck and Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Organon and Co., Orion Pharma Ltd., Otsuka Holdings Co. Ltd., Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., and UCB SA. Also, the dementia and movement disorder treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR73379

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Application
Exhibit 06: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global dementia and movement disorder treatment market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global dementia and movement disorder treatment market 2018 - 2022 ($ billion)
4.2 Application Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Application Segment 2018 - 2022 ($ billion)
4.3 Drug Class Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Drug Class Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Application

6.1 Market segments
Exhibit 30: Chart on Application - Market share 2023-2028 (%)
Exhibit 31: Data Table on Application - Market share 2023-2028 (%)
6.2 Comparison by Application
Exhibit 32: Chart on Comparison by Application
Exhibit 33: Data Table on Comparison by Application
6.3 Movement disorders - Market size and forecast 2023-2028
Exhibit 34: Chart on Movement disorders - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Movement disorders - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Movement disorders - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Movement disorders - Year-over-year growth 2023-2028 (%)
6.4 Progressive dementia - Market size and forecast 2023-2028
Exhibit 38: Chart on Progressive dementia - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Progressive dementia - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Progressive dementia - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Progressive dementia - Year-over-year growth 2023-2028 (%)
6.5 Progressive dementia with neurological abnormality (PDNA) - Market size and forecast 2023-2028
Exhibit 42: Chart on Progressive dementia with neurological abnormality (PDNA) - Market size and forecast 2023-2028 ($ billion)
Exhibit 43: Data Table on Progressive dementia with neurological abnormality (PDNA) - Market size and forecast 2023-2028 ($ billion)
Exhibit 44: Chart on Progressive dementia with neurological abnormality (PDNA) - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Progressive dementia with neurological abnormality (PDNA) - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Application
Exhibit 46: Market opportunity by Application ($ billion)
Exhibit 47: Data Table on Market opportunity by Application ($ billion)

7 Market Segmentation by Drug Class

7.1 Market segments
Exhibit 48: Chart on Drug Class - Market share 2023-2028 (%)
Exhibit 49: Data Table on Drug Class - Market share 2023-2028 (%)
7.2 Comparison by Drug Class
Exhibit 50: Chart on Comparison by Drug Class
Exhibit 51: Data Table on Comparison by Drug Class
7.3 MAO inhibitors - Market size and forecast 2023-2028
Exhibit 52: Chart on MAO inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibit 53: Data Table on MAO inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibit 54: Chart on MAO inhibitors - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on MAO inhibitors - Year-over-year growth 2023-2028 (%)
7.4 Acetylcholinesterase inhibitors - Market size and forecast 2023-2028
Exhibit 56: Chart on Acetylcholinesterase inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on Acetylcholinesterase inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on Acetylcholinesterase inhibitors - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Acetylcholinesterase inhibitors - Year-over-year growth 2023-2028 (%)
7.5 Glutamate inhibitors - Market size and forecast 2023-2028
Exhibit 60: Chart on Glutamate inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on Glutamate inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on Glutamate inhibitors - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Glutamate inhibitors - Year-over-year growth 2023-2028 (%)
7.6 Others - Market size and forecast 2023-2028
Exhibit 64: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 65: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 66: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 67: Data Table on Others - Year-over-year growth 2023-2028 (%)
7.7 Market opportunity by Drug Class
Exhibit 68: Market opportunity by Drug Class ($ billion)
Exhibit 69: Data Table on Market opportunity by Drug Class ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 71: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 73: Chart on Geographic comparison
Exhibit 74: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 UK - Market size and forecast 2023-2028
Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.10 Canada - Market size and forecast 2023-2028
Exhibit 103: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.11 France - Market size and forecast 2023-2028
Exhibit 107: Chart on France - Market size and forecast 2023-2028 ($ billion)
Exhibit 108: Data Table on France - Market size and forecast 2023-2028 ($ billion)
Exhibit 109: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibit 110: Data Table on France - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 111: Market opportunity By Geographical Landscape ($ billion)
Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 113: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 115: Overview on factors of disruption
11.4 Industry risks
Exhibit 116: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 117: Vendors covered
12.2 Market positioning of vendors
Exhibit 118: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 119: AbbVie Inc. - Overview
Exhibit 120: AbbVie Inc. - Product / Service
Exhibit 121: AbbVie Inc. - Key news
Exhibit 122: AbbVie Inc. - Key offerings
12.4 Acorda Therapeutics Inc.
Exhibit 123: Acorda Therapeutics Inc. - Overview
Exhibit 124: Acorda Therapeutics Inc. - Product / Service
Exhibit 125: Acorda Therapeutics Inc. - Key offerings
12.5 Amneal Pharmaceuticals Inc.
Exhibit 126: Amneal Pharmaceuticals Inc. - Overview
Exhibit 127: Amneal Pharmaceuticals Inc. - Business segments
Exhibit 128: Amneal Pharmaceuticals Inc. - Key news
Exhibit 129: Amneal Pharmaceuticals Inc. - Key offerings
Exhibit 130: Amneal Pharmaceuticals Inc. - Segment focus
12.6 Biogen Inc.
Exhibit 131: Biogen Inc. - Overview
Exhibit 132: Biogen Inc. - Product / Service
Exhibit 133: Biogen Inc. - Key offerings
12.7 Eisai Co. Ltd.
Exhibit 134: Eisai Co. Ltd. - Overview
Exhibit 135: Eisai Co. Ltd. - Business segments
Exhibit 136: Eisai Co. Ltd. - Key offerings
Exhibit 137: Eisai Co. Ltd. - Segment focus
12.8 H Lundbeck AS
Exhibit 138: H Lundbeck AS - Overview
Exhibit 139: H Lundbeck AS - Product / Service
Exhibit 140: H Lundbeck AS - Key offerings
12.9 Johnson and Johnson
Exhibit 141: Johnson and Johnson - Overview
Exhibit 142: Johnson and Johnson - Business segments
Exhibit 143: Johnson and Johnson - Key news
Exhibit 144: Johnson and Johnson - Key offerings
Exhibit 145: Johnson and Johnson - Segment focus
12.10 Kirin Holdings Co. Ltd.
Exhibit 146: Kirin Holdings Co. Ltd. - Overview
Exhibit 147: Kirin Holdings Co. Ltd. - Business segments
Exhibit 148: Kirin Holdings Co. Ltd. - Key offerings
Exhibit 149: Kirin Holdings Co. Ltd. - Segment focus
12.11 Lannett Co. Inc.
Exhibit 150: Lannett Co. Inc. - Overview
Exhibit 151: Lannett Co. Inc. - Product / Service
Exhibit 152: Lannett Co. Inc. - Key offerings
12.12 Merck and Co. Inc.
Exhibit 153: Merck and Co. Inc. - Overview
Exhibit 154: Merck and Co. Inc. - Business segments
Exhibit 155: Merck and Co. Inc. - Key news
Exhibit 156: Merck and Co. Inc. - Key offerings
Exhibit 157: Merck and Co. Inc. - Segment focus
12.13 Novartis AG
Exhibit 158: Novartis AG - Overview
Exhibit 159: Novartis AG - Business segments
Exhibit 160: Novartis AG - Key offerings
Exhibit 161: Novartis AG - Segment focus
12.14 Otsuka Holdings Co. Ltd.
Exhibit 162: Otsuka Holdings Co. Ltd. - Overview
Exhibit 163: Otsuka Holdings Co. Ltd. - Business segments
Exhibit 164: Otsuka Holdings Co. Ltd. - Key offerings
Exhibit 165: Otsuka Holdings Co. Ltd. - Segment focus
12.15 Supernus Pharmaceuticals Inc.
Exhibit 166: Supernus Pharmaceuticals Inc. - Overview
Exhibit 167: Supernus Pharmaceuticals Inc. - Product / Service
Exhibit 168: Supernus Pharmaceuticals Inc. - Key offerings
12.16 Teva Pharmaceutical Industries Ltd.
Exhibit 169: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 170: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 171: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 172: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 173: Teva Pharmaceutical Industries Ltd. - Segment focus
12.17 UCB SA
Exhibit 174: UCB SA - Overview
Exhibit 175: UCB SA - Product / Service
Exhibit 176: UCB SA - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 177: Inclusions checklist
Exhibit 178: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 179: Currency conversion rates for US$
13.4 Research methodology
Exhibit 180: Research methodology
Exhibit 181: Validation techniques employed for market sizing
Exhibit 182: Information sources
13.5 List of abbreviations
Exhibit 183: List of abbreviations